As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
|Articles|August 12, 2020
- Pharmaceutical Executive-08-01-2020
- Volume 40
- Issue 8
Pharmaceutical Executive, August 2020 Issue (PDF)
Click here for a link to open the Pharmaceutical Executive August 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 6 years ago
Pharm Exec’s 19th Annual Industry Auditabout 6 years ago
AI and Social Listening: Myths vs. Factsabout 6 years ago
A Good Time to ‘Revamp’ Sales and Marketingabout 6 years ago
Tapping Compliance Data to Drive Successabout 6 years ago
Pricing, Innovation, and a Pound of Fleshabout 6 years ago
Strategic Realignment for a Better Future 1about 6 years ago
Tackling a ‘Genius Virus’about 6 years ago
Leaders Need to Hit Pricing Issue Head-Onabout 6 years ago
The New Data Dynamic: How COVID-19 has Upended Modelabout 6 years ago
Making Strides in Pharma Gender ParityAdvertisement
Related to this article
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
4
Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher
5